Abstract
Human tissues differ by the type and the amount of energy substrate that they use and store, as dictated by their genetically programmed “metabolic rigidity” which defines the expression of tissue-specific catabolic and anabolic enzymes. For instance, adipocytes and neurons cannot perform fat oxidation, while cardiomyocytes utilize mainly fatty acids for ATP synthesis. These programs evolve during embryogenesis, with a typical burst of oxidative metabolism at birth. Bioenergetic homeostasis is regulated at the cellular level by effectors such as insulin and at the organismal level by the metabolic coupling between “energy donor” tissues, as the adipose tissue and the liver, and “receivers” and the muscle and the brain. In contrast to normal tissues, most tumors develop a dramatic “metabolic flexibility,” which allows them to consume whatever energy substrate is available. Yet, recent findings suggest that this flexibility is restricted by specific anabolic needs, so that alternative energy-transducing pathways are not selected randomly. Cancer cells also avoid the metabolic control by insulin, growth factors, and energy substrate starvation or excess by typical mutations in the MAPK, PI3K, RAS, and related pathways. Metabolic flexibility is made possible by the molecular rewiring of several metabolic pathways, which undergo branching, truncation, and reversal, as extensively documented for the Krebs cycle in the last decade. Like normal tissues, tumors can take advantage of metabolic coupling with other tissues, although this phenomenon remains poorly described. A related bioenergetic peculiarity of cancer cells concerns the metabolic coupling which occurs inside the tumors, between hypoxic-glycolytic and oxygenated-oxidative cancer cells. Undoubtedly, the fundamental studies on metabolic rigidity in normal tissues and on metabolic flexibility in cancer cells have revealed novel means of bioenergetic control, such as the essential signaling activity of the oncometabolites succinate, fumarate, oxoglutarate, or acetyl-CoA on HIF1α and NRF2 transcription factors, but also histone acetylases, respectively. The well-known regulation of OXPHOS by citrate, NADH, F1,6BP, Ca2+, and ATP on glycolytic enzymes IDH, PDH, and CIV also operates in cancer cells. Besides energy homeostasis, the study of cancer cell metabolic remodeling has shed light on the close links between the modalities of energy transduction and the capacity to synthesize amino acids or lipids necessary for tumor growth. Metabolic remodeling is not restricted to cancer and has been investigated in genetically inherited metabolic disorders as mitochondrial diseases or in the multifactorial metabolic syndrome. The results demonstrated the existence of alternative pathways of ATP synthesis and the effect of oxidative stress on TCA truncation via aconitase cleavage. Nowadays, large-scale analyses of comprehensive proteomics, transcriptomics, and metabolomics, potentially supported by computer modeling of metabolism and genetic approaches of subpathways validation, allow the deciphering of the fine changes in cell metabolism, both in physiology and pathology. Patterns of metabolic deviations and the corresponding genetic signatures can be confirmed by flux analyses using 13C-labeled isotopes of relevant metabolites. Analysis of deviant metabolism can identify potential targets so that therapeutic strategies could be derived from this knowledge, and ongoing preclinical studies aim to alter the alternative metabolic pathways in cancer.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Baracca A, Chiaradonna F, Sgarbi G et al (2010) Mitochondrial Complex I decrease is responsible for bioenergetic dysfunction in K-ras transformed cells. Biochim Biophys Acta 1797:314–323. doi:10.1016/j.bbabio.2009.11.006
Benard G, Bellance N, Jose C et al (2010) Multi-site control and regulation of mitochondrial energy production. Biochim Biophys Acta 1797:698–709. doi:10.1016/j.bbabio.2010.02.030, S0005-2728(10)00084-8 [pii]
Bulteau A-L, Ikeda-Saito M, Szweda LI (2003) Redox-dependent modulation of aconitase activity in intact mitochondria. Biochemistry 42:14846–14855. doi:10.1021/bi0353979
Caro P, Kishan AU, Norberg E et al (2012) Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell 22:547–560. doi:10.1016/j.ccr.2012.08.014
Chance B, Williams GR (1955) Respiratory enzymes in oxidative phosphorylation. III. The steady state. J Biol Chem 217:409–427
Chance B, Williams GR (1956) The respiratory chain and oxidative phosphorylation. Adv Enzymol Relat Areas Mol Biol 17:65–134
Cheng T, Sudderth J, Yang C et al (2011) Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci USA 108:8674–8679. doi:10.1073/pnas.1016627108
Cogliati S, Frezza C, Soriano ME et al (2013) Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency. Cell 155:160–171. doi:10.1016/j.cell.2013.08.032
Curtis JM, Hahn WS, Long EK et al (2012) Protein carbonylation and metabolic control systems. Trends Endocrinol Metab 23:399–406. doi:10.1016/j.tem.2012.05.008
De Groof AJ, te Lindert MM, van Dommelen MM et al (2009) Increased OXPHOS activity precedes rise in glycolytic rate in H-RasV12/E1A transformed fibroblasts that develop a Warburg phenotype. Mol Cancer 8:54. doi:10.1186/1476-4598-8-54, 1476-4598-8-54 [pii]
DeBerardinis RJ, Mancuso A, Daikhin E et al (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104:19345–19350. doi:10.1073/pnas.0709747104, 0709747104 [pii]
Faubert B, Boily G, Izreig S et al (2013) AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 17:113–124. doi:10.1016/j.cmet.2012.12.001
Fendt SM, Bell EL, Keibler MA et al (2013) Reductive glutamine metabolism is a function of the alpha-ketoglutarate to citrate ratio in cells. Nat Commun 4:2236. doi:10.1038/ncomms3236
Fukuda R, Zhang H, Kim JW et al (2007) HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129:111–122. doi:10.1016/j.cell.2007.01.047, S0092-8674(07)00307-8 [pii]
Gellerich FN, Gizatullina Z, Gainutdinov T et al (2013) The control of brain mitochondrial energization by cytosolic calcium: the mitochondrial gas pedal. IUBMB Life 65:180–190. doi:10.1002/iub.1131
Gnaiger E (2009) Capacity of oxidative phosphorylation in human skeletal muscle: new perspectives of mitochondrial physiology. Int J Biochem Cell Biol 41:1837–1845. doi:10.1016/j.biocel.2009.03.013, S1357-2725(09)00117-4 [pii]
Gough DJ, Corlett A, Schlessinger K et al (2009) Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 324:1713–1716. doi:10.1126/science.1171721, 324/5935/1713 [pii]
Hardie DG, Scott JW, Pan DA, Hudson ER (2003) Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 546:113–120
Hatzivassiliou G, Zhao F, Bauer DE et al (2005) ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8:311–321
Herzig S, Raemy E, Montessuit S et al (2012) Identification and functional expression of the mitochondrial pyruvate carrier. Science 337:93–96. doi:10.1126/science.1218530
James AM, Collins Y, Logan A, Murphy MP (2012) Mitochondrial oxidative stress and the metabolic syndrome. Trends Endocrinol Metab 23:429–434. doi:10.1016/j.tem.2012.06.008
Jose C, Rossignol R (2013) Rationale for mitochondria-targeting strategies in cancer bioenergetic therapies. Int J Biochem Cell Biol 45:123–129. doi:10.1016/j.biocel.2012.07.005
Jose C, Bellance N, Rossignol R (2011a) Choosing between glycolysis and oxidative phosphorylation: a tumor’s dilemma? Biochim Biophys Acta 1807:552–561. doi:10.1016/j.bbabio.2010.10.012
Jose C, Hebert-Chatelain E, Bellance N et al (2011b) AICAR inhibits cancer cell growth and triggers cell-type distinct effects on OXPHOS biogenesis, oxidative stress and Akt activation. Biochim Biophys Acta 1807:707–718
Jose C, Bellance N, Chatelain EH et al (2012) Antiproliferative activity of levobupivacaine and aminoimidazole carboxamide ribonucleotide on human cancer cells of variable bioenergetic profile. Mitochondrion 12:100–109. doi:10.1016/j.mito.2011.03.010
Jose C, Melser S, Benard G, Rossignol R (2013) Mitoplasticity: adaptation biology of the mitochondrion to the cellular redox state in physiology and carcinogenesis. Antioxid Redox Signal 18:808–849. doi:10.1089/ars.2011.4357
Lopes Costa A, Le Bachelier C, Mathieu L et al (2014) Beneficial effects of resveratrol on respiratory chain defects in patients’ fibroblasts involve estrogen receptor and estrogen-related receptor alpha signaling. Hum Mol Genet 23:2106–2119. doi:10.1093/hmg/ddt603
Lustig Y, Ruas JL, Estall JL et al (2011) Separation of the gluconeogenic and mitochondrial functions of PGC-1{alpha} through S6 kinase. Genes Dev 25:1232–1244. doi:10.1101/gad.2054711
Maddocks OD, Berkers CR, Mason SM et al (2013) Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 493:542–546. doi:10.1038/nature11743
Marin-Valencia I, Yang C, Mashimo T et al (2012a) Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab 15:827–837. doi:10.1016/j.cmet.2012.05.001
Marin-Valencia I, Cho SK, Rakheja D et al (2012b) Glucose metabolism via the pentose phosphate pathway, glycolysis and Krebs cycle in an orthotopic mouse model of human brain tumors. NMR Biomed 25:1177–1186. doi:10.1002/nbm.2787
Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D et al (2012) Ketone body utilization drives tumor growth and metastasis. Cell Cycle 11:3964–3971. doi:10.4161/cc.22137
Matoba S, Kang JG, Patino WD et al (2006) p53 regulates mitochondrial respiration. Science 312:1650–1653. doi:10.1126/science.1126863, 1126863 [pii]
Melser S, Chatelain EH, Lavie J et al (2013) Rheb regulates mitophagy induced by mitochondrial energetic status. Cell Metab 17:719–730. doi:10.1016/j.cmet.2013.03.014
Metallo CM, Gameiro PA, Bell EL et al (2012) Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481:380–384. doi:10.1038/nature10602
Mitchell P (1961) Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism. Nature 191:144–148
Morton R, Cunningham C, Jester R et al (1976) Alteration of mitochondrial function and lipid composition in Morris 7777 hepatoma. Cancer Res 36:3246–3254
Mullen AR, Wheaton WW, Jin ES et al (2012) Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481:385–388. doi:10.1038/nature10642
Niemann S, Muller U (2000) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 26:268–270
Ostojić J, Panozzo C, Lasserre J-P et al (2013) The energetic state of mitochondria modulates complex III biogenesis through the ATP-dependent activity of Bcs1. Cell Metab 18:567–577. doi:10.1016/j.cmet.2013.08.017
Palmieri F, Pierri CL (2010) Mitochondrial metabolite transport. Essays Biochem 47:37–52. doi:10.1042/bse0470037
Palorini R, Cammarata F, Balestrieri C et al (2013) Glucose starvation induces cell death in K-ras-transformed cells by interfering with the hexosamine biosynthesis pathway and activating the unfolded protein response. Cell Death Dis 4:e732. doi:10.1038/cddis.2013.257
Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812
Peinado JR, Diaz-Ruiz A, Frühbeck G, Malagon MM (2014) Mitochondria in metabolic disease: getting clues from proteomic studies. Proteomics 14:452–466. doi:10.1002/pmic.201300376
Pollard PJ, Briere JJ, Alam NA et al (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14:2231–2239
Roesch A, Vultur A, Bogeski I et al (2013) Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 23:811–825. doi:10.1016/j.ccr.2013.05.003
Rossignol R, Letellier T, Malgat M et al (2000) Tissular variation in the control of oxidative phosphorylations, implication for mitochondrial diseases. Biochem J 347:45–53
Saada A (2014) Mitochondria: mitochondrial OXPHOS (dys) function ex vivo—the use of primary fibroblasts. Int J Biochem Cell Biol 48:60–65. doi:10.1016/j.biocel.2013.12.010
Samudio I, Harmancey R, Fiegl M et al (2010) Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 120:142–156. doi:10.1172/JCI38942
Schagger H (2001) Blue-native gels to isolate protein complexes from mitochondria. Methods Cell Biol 65:231–244
Schägger H, Pfeiffer K (2000) Supercomplexes in the respiratory chains of yeast and mammalian mitochondria. EMBO J 19:1777–1783
Scheffler IE (1999) Mitochondria. Wiley-Liss, New York, 364 p
Scotland S, Saland E, Skuli N et al (2013) Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells. Leukemia 27:2129–2138. doi:10.1038/leu.2013.107
Son J, Lyssiotis CA, Ying H et al (2013) Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496:101–105. doi:10.1038/nature12040
Telang S, Lane AN, Nelson KK et al (2007) The oncoprotein H-RasV12 increases mitochondrial metabolism. Mol Cancer 6:77. doi:10.1186/1476-4598-6-77, 1476-4598-6-77 [pii]
Warburg O (1930) Metabolism of tumors. Arnold Constable, London
Wei B-R, Simpson RM, Johann DJ et al (2012) Proteomic profiling of H-Ras-G12V induced hypertrophic cardiomyopathy in transgenic mice using comparative LC-MS analysis of thin fresh-frozen tissue sections. J Proteome Res 11:1561–1570. doi:10.1021/pr200612y
Weinberg F, Hamanaka R, Wheaton WW et al (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 107:8788–8793. doi:10.1073/pnas.1003428107
Weinhouse S (1956) On respiratory impairment in cancer cells. Science 124:267–268
Wellen KE, Hatzivassiliou G, Sachdeva UM et al (2009) ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324:1076–1080. doi:10.1126/science.1164097
Wise DR, DeBerardinis RJ, Mancuso A et al (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105:18782–18787. doi:10.1073/pnas.0810199105, 0810199105 [pii]
Ye J, Mancuso A, Tong X et al (2012) Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci USA 109:6904–6909. doi:10.1073/pnas.1204176109
Zhang Z, Falk MJ (2014) Integrated transcriptome analysis across mitochondrial disease etiologies and tissues improves understanding of common cellular adaptations to respiratory chain dysfunction. Int J Biochem Cell Biol 50:106–111. doi:10.1016/j.biocel.2014.02.012
Zhang Z, Tsukikawa M, Peng M et al (2013) Primary respiratory chain disease causes tissue-specific dysregulation of the global transcriptome and nutrient-sensing signaling network. PLoS One 8:e69282. doi:10.1371/journal.pone.0069282
Zirath H, Frenzel A, Oliynyk G et al (2013) MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc Natl Acad Sci USA 110:10258–10263. doi:10.1073/pnas.1222404110
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Wien
About this chapter
Cite this chapter
Obre, E., Rossignol, R. (2015). Metabolic Remodeling in Bioenergetic Disorders and Cancer. In: Mazurek, S., Shoshan, M. (eds) Tumor Cell Metabolism. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1824-5_1
Download citation
DOI: https://doi.org/10.1007/978-3-7091-1824-5_1
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-1823-8
Online ISBN: 978-3-7091-1824-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)